Interferon-associated retinopathy risk in patients with diabetes and hypertensive hepatitis C

Table 1 Main characteristics of the studies included in the meta-analysis

Ref.	Year	Country	Study design	Type of IFN	No. of HCV (+) IAR (+) cases/HCV (+) IAR (-) controls	Reported end-points	Follow-up	Study quality
Kawano et al[11]	1996	Japan	Prospective cohort	Natural IFN α, recombinant IFN α-2a/2b	17/49	Retinopathy	48 wk	5
Okuse et al[19]	2006	Japan	Prospective cohort	Recombinant IFN α-2b	18/56	Retinopathy	24 wk	6
d'Alteroche et al[25]	2006	France	Prospective cohort	IFN α, PIFN α	11/133	Retinopathy	72 wk	6
Panetta et al[21]	2009	United States	Retrospective cohort	Consensus IFN, PIFN α-2a/2b	114/48	Retinopathy	48 wk	5
Mehta et al[20]	2010	United States	Retrospective cohort	PIFN	26/39	Retinopathy	48 wk	4
Kim et al[18]	2010	South Korea	Prospective cohort	PIFN, conventional IFN	13/22	Retinopathy	36 wk	8
Vujosevic et al[26]	2012	Canada	Prospective cohort	PIFNα-2a/2b	22/66	Retinopathy	36/60 wk	8
Mousa et al[22]	2013	Egypt	Prospective cohort	PIFN α-2a/2b	40/42	Retinopathy	48 wk	6

IFN: Interferon; PIFN: Pegylated interferon.